The commonly used targets of immunotherapy are mainly cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or PD-1/PD-L1, which can effectively treat a variety of malignant tumors (58). This evidence concerns the gene CTLA4 and cancer.